Warby Parker Inc. WRBY R2K
Healthcare · Medical Instruments & Supplies · United States
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
READ MORE ›$24.52
+15.82% 1Y
Market & Price
Market Cap
$3.01B
Current Price
$24.52
High / Low (52W)
$30.23 / $16.49
Beta
1.96
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
36.40
PEG Ratio
-
Book Value
$3.06
Price to Book
8.01
P/S
3.38
EV/EBITDA
64.17
Dividend Yield
-
Profitability & Returns
ROCE
-0.93%
ROE
0.37%
ROA
-0.51%
Profit Margin
0.15%
Op Margin
0.95%
EPS (Latest Qtr)
$0.03
EPS (TTM)
$0.01
Balance Sheet & Liquidity
Debt/Equity
0.63
Quick Ratio
1.89
Current Ratio
2.33
Debt
$237.63M
Total Assets
$720.92M
Current Assets
$352.44M
Working Capital
$202.31M
Ownership
Promoter Holding
5.72%
Chg in Prom Hold
-
FII / Inst Holding
102.29%
Chg in FII Hold
0.05%
Financial Snapshot
Enterprise Value
$2.96B
Total Revenue (TTM)
$890.57M
EBITDA
$46.10M
Free Cash Flow
$32.27M
Operating Cash Flow
$105.94M
Shares Outstanding
107.09M
Gross Margin
53.41%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
13.39%
Profit 5Y
33.83%
Revenue (YoY)
8.30%
Earnings (YoY)
-9.60%
PROS
- Compounding revenue at 13.4% over 5 years.
- Profit CAGR of 33.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WRBY Warby Parker Inc. R2K | 24.52 | - | $3.01B | - | -0.93% | 0.37% | 13.39% | 33.83% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 104.09M | 138.97M | 131.56M | 137.37M | 153.22M | 149.62M | 148.78M | 171.97M | 166.09M | 169.85M | 200.00M | 188.22M | - | - | 223.78M | 214.47M | 221.68M | 211.97M | 242.45M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.80M | 100.87M | 101.73M | 100.92M | 111.41M |
| Gross Profit | - | - | 63.98M | 83.78M | 78.05M | 79.66M | 89.65M | 86.35M | 84.42M | 94.79M | 90.64M | 92.73M | 113.46M | 105.38M | - | - | 125.98M | 113.61M | 119.94M | 111.04M | 131.04M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 123.51M | 118.13M | 116.38M | 117.89M | 129.37M |
| Operating Income | - | - | -41.34M | 3.02M | -8.81M | -91.98M | -33.74M | -32.08M | -23.67M | -12.43M | -18.23M | -19.77M | -5.13M | -8.96M | - | - | 2.47M | -4.53M | 3.57M | -6.85M | 1.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.63M | 7.96M | 16.10M | 6.25M | 15.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.93M | -2.54M | 5.75M | -5.09M | 4.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45M | -789.00K | -125.00K | 862.00K | 821.00K |
| Net Income | 2.78M | -12.79M | -41.61M | 3.01M | -10.31M | -91.07M | -34.13M | -32.17M | -10.81M | -10.81M | -15.93M | -17.41M | -2.68M | -6.76M | - | - | 3.47M | -1.75M | 5.87M | -5.95M | 3.18M |
| Diluted EPS | - | - | -0.78 | -0.03 | -0.35 | -1.45 | -0.30 | -0.28 | -0.21 | -0.09 | -0.14 | -0.15 | -0.02 | -0.06 | - | - | 0.03 | -0.01 | 0.05 | -0.05 | 0.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 370.46M | 393.72M | - | 598.11M | 669.76M | 771.32M | 871.90M |
| Cost of Revenue | - | - | - | 257.05M | 304.54M | 344.48M | 401.33M |
| Gross Profit | 223.11M | 231.94M | - | 341.06M | 365.22M | 426.83M | 470.58M |
| Operating Expenses | - | - | - | 452.26M | 437.22M | 456.95M | 475.92M |
| Operating Income | -1.66M | -55.63M | - | -111.20M | -72.00M | -30.11M | -5.34M |
| EBITDA | - | - | - | -79.34M | -33.44M | 15.75M | 44.94M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -109.90M | -62.76M | -19.52M | 3.04M |
| Tax Provision | - | - | - | 497.00K | 433.00K | 875.00K | 1.40M |
| Net Income | 0 | -55.92M | - | -110.39M | -63.20M | -20.39M | 1.64M |
| Diluted EPS | -1.10 | -1.05 | -2.21 | -0.96 | -0.54 | -0.17 | - |
Compounded Sales Growth
| 5 Years: | 13.39% |
| 1 Year: | 8.30% |
Compounded Profit Growth
| 5 Years: | 33.83% |
| 1 Year: | -9.60% |
Stock Price Performance
| 1 Year: | +15.82% |
| 6 Months: | +22.66% |
| 3 Months: | -1.96% |
| 1 Month: | +14.21% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 444.75M | - | 568.71M | 580.31M | 676.49M | 720.92M |
| Current Assets | - | - | - | - | 294.57M | 298.62M | 326.05M | 352.44M |
| Cash & Equivalents | - | - | 314.08M | - | 208.59M | 216.89M | 254.16M | 286.36M |
| Inventory | - | - | - | - | 68.85M | 62.23M | 52.34M | 44.51M |
| Receivables | - | - | - | - | 1.44M | 1.78M | 1.95M | 3.29M |
| Total Liabilities | - | - | 136.34M | - | 282.06M | 278.52M | 336.42M | 353.19M |
| Current Liabilities | - | - | 105.33M | - | 129.56M | 127.09M | 130.35M | 150.13M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 173.38M | 174.46M | 225.35M | 233.15M |
| Total Equity | -133.59M | -189.45M | -198.10M | - | 286.65M | 301.79M | 340.07M | 367.73M |
| Shares Outstanding | - | - | - | - | 115.34M | 118.16M | 120.85M | 122.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 21.39M | 32.76M | - | 10.37M | 60.99M | 98.74M | 110.78M |
| Investing Cash Flow | -32.63M | -20.07M | - | -60.18M | -54.67M | -66.03M | -67.05M |
| Financing Cash Flow | -83.36M | 245.94M | - | 3.29M | 2.87M | 4.96M | -12.00M |
| Capital Expenditure | -32.63M | -20.07M | - | -60.18M | -53.67M | -64.03M | -67.05M |
| Free Cash Flow | -11.24M | 12.69M | - | -49.81M | 7.32M | 34.71M | 43.74M |
| Net Change in Cash | - | - | - | -46.52M | 9.19M | 37.67M | 31.74M |
| Share Buybacks | 79.47M | 0 | 8.09M | 0 | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 60.2% | 58.9% | - | 57.0% | 54.5% | 55.3% | 54.0% |
| Operating Margin % | -0.4% | -14.1% | - | -18.6% | -10.7% | -3.9% | -0.6% |
| Net Margin % | 0.0% | -14.2% | - | -18.5% | -9.4% | -2.6% | 0.2% |
| ROE % | -0.0% | 28.2% | - | -38.5% | -20.9% | -6.0% | 0.4% |
| ROCE % | - | -16.4% | - | -25.3% | -15.9% | -5.5% | -0.9% |
Shareholding Pattern
Insiders
5.72%
Institutions
102.29%
Public Float
108.50%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.50% | 15.53M | $380.71M |
| 2 | JPMORGAN CHASE & CO | 9.42% | 10.09M | $247.36M |
| 3 | Blackrock Inc. | 6.78% | 7.26M | $177.99M |
| 4 | Durable Capital Partners Lp | 5.97% | 6.40M | $156.84M |
| 5 | Vanguard Portfolio Management LLC | 4.98% | 5.33M | $130.73M |
| 6 | Vanguard Capital Management LLC | 4.11% | 4.40M | $107.97M |
| 7 | Vaughan Nelson Investment Management, L.P. | 2.83% | 3.03M | $74.25M |
| 8 | State Street Corporation | 2.26% | 2.42M | $59.43M |
| 9 | Geode Capital Management, LLC | 2.22% | 2.37M | $58.22M |
| 10 | Fuller & Thaler Asset Management Inc. | 2.16% | 2.31M | $56.71M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WRBY
No recent headlines available.